Pfizer licenses 3SBio cancer drug for $1.25B upfront

JHVEPhoto/iStock Editorial via Getty Images

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug candidate, SSGJ-707.

SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, is currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic